Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
23.16
0.87 (3.90%)
At close: Oct 08, 2025, 10:16 AM
3.90% (1D)
| Bid | 23.13 |
| Market Cap | 17.2B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -746.08M |
| EPS (ttm) | -1.02 |
| PE Ratio (ttm) | -22.71 |
| Forward PE | -33.06 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 23.23 |
| Volume | 522,635 |
| Avg. Volume (20D) | 3,749,653 |
| Open | 22.48 |
| Previous Close | 22.29 |
| Day's Range | 22.39 - 23.35 |
| 52-Week Range | 15.55 - 36.91 |
| Beta | -1.14 |
| Ex-Dividend Date | n/a |
About SMMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SMMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsSummit Therapeutics Inc. is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+7.05%
Summit Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
3 weeks ago
+1.83%
Summit Therapeutics shares are trading higher after the company disclosed co-CEOs each purchased 338,394 shares at an average price of $17.69.
4 weeks ago · proactiveinvestors.com
Summit Therapeutics shares fall as lung cancer trial results disappointSummit Therapeutics PLC (NASDAQ:SMMT) shares dropped sharply on Monday following the release of mixed results from its Phase III HARMONi trial of ivonescimab, a potential lung cancer therapy. The stoc...